Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01113801 · ClinicalTrials.gov registry record · Phase 2
A Study in Participants With Diabetic Kidney Disease
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 417
- Enrollment target
NCT01113801: Clinical Trial Phase 2 study, sponsored by Eli Lilly and Company.
NCT01113801 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 417 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (214% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01113801, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 417 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
Primary Outcome
Analysis of covariance (ANCOVA) model was used with treatment, visit, and treatment-by-visit interaction as fixed effects, subject as random effect, baseline Serum Creatinine log transformed (ln) and first morning urine protein to creatinine ratio (PCR) log transformed (ln) as covariates.
Interventions
- DRUG Placebo
- DRUG LY2382770
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 417 participants |
| Start Date | 2010-07 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Why NCT01113801 stopped before completion
NCT01113801 is an interventional study that assigns participants to a tested intervention. The registered 417 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (214% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01113801 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01113801 about?
NCT01113801 is a clinical study titled "A Study in Participants With Diabetic Kidney Disease". The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
What is the current status of trial NCT01113801?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 417 participants. The study started on 2010-07. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01113801?
The interventions under investigation include: Placebo (DRUG), LY2382770 (DRUG).
Who is sponsoring clinical trial NCT01113801?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01113801's enrollment target sits among peer trials
417 91st of 2000 higher than 1,910 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06169735 · 417 participants · Phase 4
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
- NCT06699901 · 417 participants
Antibiotic Concentrations After MassivE Transfusion Study
- NCT03135886 · 418 participants · NA
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia